메뉴 건너뛰기




Volumn 54, Issue 79, 2007, Pages 2141-2145

A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients

Author keywords

Gemcitabine; GOFT; Oxaliplatin; Pancreatic adenocarcinoma; Thalidomide

Indexed keywords

FLUOROURACIL; GEMCITABINE; OXALIPLATIN; THALIDOMIDE;

EID: 37749009156     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (4)

References (23)
  • 1
    • 0028799366 scopus 로고
    • The National Cancer Data Base report on pancreatic cancer
    • Niederhuber JE, Brennan MF, Menck HR: The National Cancer Data Base report on pancreatic cancer. Cancer 1995; 76:1671-1677.
    • (1995) Cancer , vol.76 , pp. 1671-1677
    • Niederhuber, J.E.1    Brennan, M.F.2    Menck, H.R.3
  • 2
    • 0037258111 scopus 로고    scopus 로고
    • The medical management of pancreatic cancer: A review
    • McKenna S, Eatock M: The medical management of pancreatic cancer: A review. The Oncologist 2003; 8:149-160.
    • (2003) The Oncologist , vol.8 , pp. 149-160
    • McKenna, S.1    Eatock, M.2
  • 3
    • 0041335589 scopus 로고    scopus 로고
    • New perspectives in the management of pancreatic cancer
    • Heller DG: New perspectives in the management of pancreatic cancer. Semin Oncol 30(Suppl 11):3-10.
    • Semin Oncol , vol.30 , Issue.SUPPL. 11 , pp. 3-10
    • Heller, D.G.1
  • 4
    • 0036962459 scopus 로고    scopus 로고
    • New Tech niques and agents in the adjuvant therapy of pancreatic cancer
    • Raraty MGT, Magee CJ, Ghaneh P, et al: New Tech niques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncologica 2002; 41:582-595.
    • (2002) Acta Oncologica , vol.41 , pp. 582-595
    • Raraty, M.G.T.1    Magee, C.J.2    Ghaneh, P.3
  • 5
    • 8244254377 scopus 로고    scopus 로고
    • Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreatic cancer: A randomized trial
    • Burris HA, Morre MJ, Anderson J, et al: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 1997; 15:2403-2413.
    • (1997) J Clin Oncol , vol.15 , pp. 2403-2413
    • Burris, H.A.1    Morre, M.J.2    Anderson, J.3
  • 6
    • 0035165047 scopus 로고    scopus 로고
    • Gemcitabine: Progress in the treatment of pancreatic cancer
    • Heinemann V: Gemcitabine: Progress in the treatment of pancreatic cancer. Oncology 2001; 60:8-18.
    • (2001) Oncology , vol.60 , pp. 8-18
    • Heinemann, V.1
  • 7
    • 0033638288 scopus 로고    scopus 로고
    • The role of gemcitabine alone and in combination in the treatment of pancreatic cancer
    • Oettle H, Arnold D, Hempel C, et al: The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anti-Cancer Drugs 2000; 11:771-786.
    • (2000) Anti-Cancer Drugs , vol.11 , pp. 771-786
    • Oettle, H.1    Arnold, D.2    Hempel, C.3
  • 8
    • 8944261362 scopus 로고    scopus 로고
    • A phase II trial of gemcitabine in patients with 5-FU-refractory pancreatic cancer
    • Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreatic cancer. Ann Oncol 1996; 7:347-353.
    • (1996) Ann Oncol , vol.7 , pp. 347-353
    • Rothenberg, M.L.1    Moore, M.J.2    Cripps, M.C.3
  • 9
    • 0142063360 scopus 로고    scopus 로고
    • The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas
    • Hoff PM, Fuchs CS: The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas. Semin Oncol 2003; 30(Suppl 15):54-61.
    • (2003) Semin Oncol , vol.30 , Issue.SUPPL. 15 , pp. 54-61
    • Hoff, P.M.1    Fuchs, C.S.2
  • 10
    • 0032990022 scopus 로고    scopus 로고
    • Supraadditive effect of 2′, 2′-difluorodeoxycystidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
    • Faivre S, Raymond E, Woynarowski JM, et al: Supraadditive effect of 2′, 2′-difluorodeoxycystidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44:117-123.
    • (1999) Cancer Chemother Pharmacol , vol.44 , pp. 117-123
    • Faivre, S.1    Raymond, E.2    Woynarowski, J.M.3
  • 11
    • 3142577828 scopus 로고    scopus 로고
    • Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: A study of the German Testicular Cancer Study Group
    • Kollmannsberger C, Beyer J, Liersch R, et al: Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004; 22:108-114.
    • (2004) J Clin Oncol , vol.22 , pp. 108-114
    • Kollmannsberger, C.1    Beyer, J.2    Liersch, R.3
  • 12
    • 0031012340 scopus 로고    scopus 로고
    • Changes in nutritional status associated with unresectable pancreatic cancer
    • Wigmore SJ, Plester CE, Richardson RA, Fearon KC: Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 1997; 75:106-109.
    • (1997) Br J Cancer , vol.75 , pp. 106-109
    • Wigmore, S.J.1    Plester, C.E.2    Richardson, R.A.3    Fearon, K.C.4
  • 13
    • 0026080801 scopus 로고
    • Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
    • Sampaio EP, Sarno EN, Galilly R, et al: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
    • (1991) J Exp Med , vol.173 , pp. 699-703
    • Sampaio, E.P.1    Sarno, E.N.2    Galilly, R.3
  • 14
    • 15444379633 scopus 로고    scopus 로고
    • Thalidomide in the treatment of cancer cachexia: A randomized placebo controlled trial
    • Gordon JN, Trebble TM, Ellis RD, et al: Thalidomide in the treatment of cancer cachexia: a randomized placebo controlled trial. Gut 2005; 54:540-545.
    • (2005) Gut , vol.54 , pp. 540-545
    • Gordon, J.N.1    Trebble, T.M.2    Ellis, R.D.3
  • 15
    • 0642375736 scopus 로고    scopus 로고
    • The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents
    • Chowbay B, Sharma A, Zhou QY, et al: The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents. Oncol Rep 2003; 10:745-751.
    • (2003) Oncol Rep , vol.10 , pp. 745-751
    • Chowbay, B.1    Sharma, A.2    Zhou, Q.Y.3
  • 16
    • 0035976547 scopus 로고    scopus 로고
    • A scheme for a dose-escalation study when event is lagged
    • Husing J, Sauerwein W, Hideghety K, et al: A scheme for a dose-escalation study when event is lagged. Statist Med 2001; 20:3323-3334.
    • (2001) Statist Med , vol.20 , pp. 3323-3334
    • Husing, J.1    Sauerwein, W.2    Hideghety, K.3
  • 17
    • 0035884462 scopus 로고    scopus 로고
    • The continual reassessment method and its applications: A Bayesian methodology for phase I cancer clinical trials
    • Ishizuka N, Ohashi Y: The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials. Statist Med 2001; 20:2661-2668.
    • (2001) Statist Med , vol.20 , pp. 2661-2668
    • Ishizuka, N.1    Ohashi, Y.2
  • 18
    • 0000106419 scopus 로고
    • Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines
    • Bergman AM, Ruiz van Haperen VWT, Veerman G, et al: Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines. Purine Pyrimidine Metab Man 1995; 7:139-143.
    • (1995) Purine Pyrimidine Metab Man , vol.7 , pp. 139-143
    • Bergman, A.M.1    Ruiz van Haperen, V.W.T.2    Veerman, G.3
  • 19
    • 0035425508 scopus 로고    scopus 로고
    • Phase II study of gemcitable and cisplatin in the tratment of patients with advanced pancreatic cancer
    • Philip PA, Zalupski MM, Vaitkevicius VK, et al: Phase II study of gemcitable and cisplatin in the tratment of patients with advanced pancreatic cancer. Cancer 2001; 92:569-577.
    • (2001) Cancer , vol.92 , pp. 569-577
    • Philip, P.A.1    Zalupski, M.M.2    Vaitkevicius, V.K.3
  • 20
    • 0036682041 scopus 로고    scopus 로고
    • Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
    • Berlin JD, Catalano P, Thomas JP, et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20:3270-3275.
    • (2002) J Clin Oncol , vol.20 , pp. 3270-3275
    • Berlin, J.D.1    Catalano, P.2    Thomas, J.P.3
  • 21
    • 0036052558 scopus 로고    scopus 로고
    • Cellular and molecular pharmacology of oxaliplatin
    • Raymond E, Faivre S, Chaney S, et al: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1:227-235.
    • (2002) Mol Cancer Ther , vol.1 , pp. 227-235
    • Raymond, E.1    Faivre, S.2    Chaney, S.3
  • 22
    • 0037087787 scopus 로고    scopus 로고
    • Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma. Final results of a GERCOR multicenter phase II study
    • Louvet C, Andre T, Lledo G, et al: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma. Final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20:1512-1518.
    • (2002) J Clin Oncol , vol.20 , pp. 1512-1518
    • Louvet, C.1    Andre, T.2    Lledo, G.3
  • 23
    • 9244226015 scopus 로고    scopus 로고
    • Hepatocellular carcinoma with intra-atrial tumor thrombi
    • Chang JY, Ka WS, Chao TY, et al: Hepatocellular carcinoma with intra-atrial tumor thrombi. Oncoly 2004; 67:320-325.
    • (2004) Oncoly , vol.67 , pp. 320-325
    • Chang, J.Y.1    Ka, W.S.2    Chao, T.Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.